GleamWall
中文EN

KRSA Korsana Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1755237 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-264.6%
TTM EPS YoY169.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-42.2%
ROA-33.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.00x
Current ratio10.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.07M$2.00M
R&D expense$959,000$286,000
SG&A expense$6.09M$5.34M
Operating income-$4.97M-$3.63M
Pretax income-$3.53M-$3.06M
Income tax$0$0
Net income-$3.53M-$3.06M
EPS (basic)-1.11-1.21
EPS (diluted)-1.11-1.21
Weighted avg. shares (diluted)3.18M2.52M
Balance sheet
Cash & equivalents$154.13M$10.11M
Receivables$1.00M$556,000
Current assets$154.60M$4.22M
PP&E, net$0$0
Total assets$154.60M$9.57M
Current liabilities$12.49M$725,000
Total liabilities$13.03M$725,000
Shareholders' equity-$33.97M$66,000
Shares outstanding1.24M2.55M
Cash flow statement
Operating cash flow-$3.31M-$4.33M
Investing cash flow—$0
Financing cash flow$3.32M$0
Stock-based compensation$441,000$625,000

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.